Peptide oral-delivery application: capsule within capsule — EP4757825A1
Filip Majewski · 2026 · EP4757825A1 · patent family 88092942
Published 2026-06-17.
Reported patent results
Reported findings
The nested-capsule formulation produced higher measured plasma concentrations than two comparator preparations.
Oral Epithalon formulation comparison described as administration to “a patient”; participant count, study order and variability are not established.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Epithalon plasma concentration | 430 pg/mL versus 360 and 310 pg/mL | Example 50 versus nested-capsule and mixed-capsule comparators · 60 minutes |
| Epithalon plasma concentration | 22,300 pg/mL versus 18,600 and 3,000 pg/mL | Example 50 versus CE-3 and mixed-capsule comparator · 120 minutes |
| Sampling window | Blood concentrations followed for 0–360 minutes | Absolute bioavailability and clinical outcomes are not established |
A patient example with unestablished replication, HPLC specificity and measurement variability cannot validate oral clinical efficacy or a reliable bioavailability ratio. The values concern this Epithalon formulation, not every peptide listed in the claims.
Source for the extracted data ↗ · Checked 2026-11-06
Patent claims and provenance
Formulation. This 2026 European publication belongs to the same family as WO2025037993A1 and describes oral peptide-delivery compositions.
Formulation claims and examples do not establish oral bioavailability or clinical equivalence for every listed peptide; this is separate from the older EP4226918 family.
- Publication
- EP4757825A1 ↗ · 2026-06-17
- Earliest priority / filing
- 2023-08-13 / 2023-08-13
- Original applicant / assignee
- Individual
- Indexed status
- Pending · checked 2026-11-06
- Patent family
- 88092942 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Dosage form for peptide agents
Inventors: Filip Majewski.
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- Formulation claims and examples do not establish oral bioavailability or clinical equivalence for every listed peptide; this is separate from the older EP4226918 family.
- A patient example with unestablished replication, HPLC specificity and measurement variability cannot validate oral clinical efficacy or a reliable bioavailability ratio. The values concern this Epithalon formulation, not every peptide listed in the claims.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; the record gives its source-check date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Original patent text and indexed metadata
Review depth: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Related-report group: patent-family-88092942. Reports in this group are not assumed to be independent trials.
Source access and review scope
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Recorded source-check date: 2026-11-06. This date does not imply a completed systematic review.
Source type: Patent publication
Citation and original source
Original source: Filip Majewski. Peptide oral-delivery application: capsule within capsule — EP4757825A1 EP4757825A1 · patent family 88092942 2026.
Molekul research summary: https://molekul.io/research/patent-ep4757825a1. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry